The medication is indicated for adults with Staphylococcus aureus bloodstream infections, including right-sided infective endocarditis; acute bacterial skin and skin structure infections; and community-acquired bacterial pneumonia. It is also approved for children with bacterial pneumonia.
In a trial to evaluate its effectiveness in treating S. aureus, Zevtera (ceftobiprole medocaril sodium for injection) was compared to daptomycin and another optional antibiotic, aztreonam. Researchers tested for survival, symptom improvement, S. aureus bacteremia bloodstream clearance, no new S. aureus bacteremia complications, and no use of other potentially effective antibiotics.
After 70 days, 69.8% of Zevtara patients and 68.7% of the other cohort achieved overall success.
Basilea Pharmaceutica International is the manufacturer of Zevtara, which achieved the FDA’s priority review, fast track and qualified infectious disease product designations.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
